Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

Moving up:

Central European Media Enterprises CETV - up 20% - Reports Q4 EPS of $(0.72); Revenue of $237.90M.
OmniVision Technologies OTVI - up 15% - Reports Q3 EPS of $0.69 vs $0.35 Est; Revenue of $352.0M vs $326.63M Est. Sees Q4 EPS $0.19-0.35 vs $0.22 Est; Sees Sales $275.0M-305.0M vs $284.40M Est.
MercadoLibre MELI - up 12.5% - Reports Q4 EPS of $0.93 vs $0.78 Est; Revenue of $134.60M vs $132.88M Est. Upgraded from Sell to Buy with $130 price target by Stifel Nicolaus.
Renewable Energy Group REGI - up 6% - Reports Q4 EPS of $0.80 vs $0.75 Est; Revenue of $391.0M vs $347.17M Est.
Galena Biopharma GALE - up 6% - NeuVax Patent Acceptance in Australia.
Sohu.com SOHU - up 5.5% - Marbridge reported that Sohu and Tencent are in talks to merge video businesses.
Celsion CLSN - up 4.5% - Reports positive interim data from Phase 2 DIGNITY trial in breast cancer.
Salix Pharmaceuticals SLXP - up 5% - Reports Q4 EPS of $1.06 vs $0.93 Est; Revenue of $257.60M vs $247.29M Est. Sees FY2014 EPS $6.46.
Splunk SPLK - up 4.5% - Reports Q4 EPS of $0.03 vs $0.05 Est; Revenue of $99.90M vs $90.36M Est. Bank of America maintains Buy on Splunk Inc., raises price objective to $100.00.
3D Systems DDD - up 4% - Reports Q4 EPS of $0.19 vs $0.20 Est; Revenue of $154.80M vs $155.07M Est; Reaffirms Outlook.

Moving down:

Endologix ELGX - down 24% - Reported Q4 GAAP Loss of $0.05/Share vs Loss of $0.02/Share Est., Sales $35.2M vs $36.9M Est.; Said Expecting FY14 Sales $146-152M vs $161.2M Est.
Deckers DECK - down 12% - Reports Q4 EPS of $4.04 vs $3.77 Est. Sees Q1 EPS $(0.16) vs $0.10 Est.
Medivation MDVN - down 10.5% - Reports Q4 EPS of $0.03 vs $(0.08) Est; Revenue of $96.60M vs $72.68M Est.
Compugen CGEN - down 10.4 - Prices 6M Share Public Offering at $10.50 per Share.
Arena Pharmaceuticals ARNA - down 7% - Reports Q4 EPS of $(0.11) vs $0.02 Est; Revenue of $6.52M, Up 236% YOY.
Pier 1 Imports PIR - down 5.7% - Sees Q4 Sales $512M-$514M vs $541.65M Est. Cuts Q4 EPS View to $0.40-$0.41 vs $0.51 Est.
Halozyme Therapeutics HALO - down 3.8% - Reports Q4 EPS of $(0.19) vs $(0.17) Est.
Northern Oil & Gas NOG - down 3.7% - Reports Q4 EPS of $0.22 vs $0.27 Est; Revenue of $101.90M vs $98.45M Est.
Questcor QCOR - down 3.2% - Citron Research reveals that the company's Achtar gel is at risk of being pulled by the FDA.
Enzymotec ENZY - down 3% - Reports Q4 EPS of $0.15 vs $0.11 Est; Revenue of $18.50M vs $18.77M Est.
United Continental UAL - down 2% - Expecting Q1 Capacity Lower Than View, Cites Weather, Sees PRASM Down 0.5-2.5%.
InterMune ITMN - down 2% - Downgrades InterMune, Inc. to Neutral, Maintains $33.00 PT, Balanced Risk/Reward is Reflected in Price.